MedTrace Logo

AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

NCT03263611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-10-12

No results posted yet for this study

Summary

This clinical trial evaluate the safety, tolerability and exploratory efficacy of targeted single injection of AMG0103 in subject with chronic discogenic lumbar back pain

Conditions

  • Degenerative Disc Disease

Interventions

DRUG

Placebo

single intradiscal injection

DRUG

AMG0103

single intradiscal injection

Sponsors & Collaborators

  • AnGes, Inc.

    lead INDUSTRY

Principal Investigators

  • AnGes, Inc. Clinical Development · AnGes, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-26
Primary Completion
2021-02-15
Completion
2021-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03263611 on ClinicalTrials.gov